ArticleAntibiotics (Basel, Switzerland)2024
Repurposing Farnesol for Combating Drug-Resistant and Persistent Single and Polymicrobial Biofilms.
Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Resilience of the Skin Microbiome in Atopic Dermatitis During Short-Term Topical Treatment.International journal of molecular sciences · 2025Trial
- Bacterial-fungal interactions: connections and consequences.Essays in biochemistry · 2026Review
- Bacterial culture and antibiotic resistance pattern in chronic rhinosinusitis among patients who underwent sinus surgery.BMC infectious diseases · 2026Article
- Farnesol, the farnesol pathway, and the immune-gut-brain axis.Frontiers in pharmacology · 2026Review
- Farnesol emulsion for elimination ofBiofilm · 2025Article
- Review
- The butterfly effect: collateral damage and impacts of antimicrobial strategies on the oral microbiome.npj antimicrobials and resistance · 2025Review
- Exploring propolis-derived compounds as quorum sensing inhibitors for Candida albicans: a molecular docking and dynamics simulations study.Scientific reports · 2025Article
- Polymicrobial Biofilms: Interkingdom Interactions, Resistance and Therapeutic Strategies.Microbial biotechnology · 2025Review
- Bioconversion of Alpha-Cembratriene-4,6-diol into High-Value Compound Farnesal Through Employment of a NovelMolecules (Basel, Switzerland) · 2025Article
- Farnesol Emulsion as an Effective Broad-Spectrum Agent against ESKAPE Biofilms.Antibiotics (Basel, Switzerland) · 2024Article
- Deciphering the Antibacterial Mechanisms of 5-Fluorouracil inAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilm-associated infections caused by drug-resistant and persistent bacteria remain a significant clinical challenge. Here we report that farnesol, commercially available as a cosmetic and flavoring agent, shows significant anti-biofilm properties when dissolved in ethanol using a proprietary formulation emulsion technique. Farnesol in the new formulation inhibits biofilm formation and disrupts established biofilms for Gram-positive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.